Pfizer and Optum researchers compared pain treatments in newly diagnosed fibromyalgia (FM) patients, suggesting new clinical practices to improve disease management. The study entitled "Evaluating Guideline-recommended Pain Medication Use Among Patients with Newly Diagnosed Fibromyalgia" was published in the journal Pain Practice. FM, a chronic pain condition, affects approximately 2%-6% of the population in the United States. The disease is diagnosed between the ages of 20 and 50 years, and impacts on the working population, reducing productivity and carrying great health care costs. Various treatment guidelines recommend slightly different pain medications. The Canadian and American guidelines suggest the use of antidepressants, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and anti-convulsants/anti-epileptic drugs (AEDs). Opioids, special weak opioids, are only recommend for patients with moderate to severe pain who are unresponsive to all other treatments. European guidelines are against the use of corticosteroids and strong opioids.